NeuroSense amends JonesTrading equity distribution agreement for up to $3.79 million share sales

• NeuroSense amended its JonesTrading Capital on Demand sales agreement to align it with a new Form F-3 registration statement.
• The updated prospectus supplement permits sales of ordinary shares with an aggregate offering price up to $3.79 million.
• 6,762,825 ordinary shares have been sold under the program for net proceeds of about $6.7 million.
• The SEC declared the new Form F-3 effective on July 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-083984), on July 31, 2026, and is solely responsible for the information contained therein.